Sage Journals: Discover world-class research

Retricted access

Research article

First published 2013-4

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Anke Vennegoor, Theo Rispens, Eva MM Strijbis [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2018-5

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Zoé LE van Kempen, Cyra E Leurs, Birgit I Witte [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2017-6

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations

Zoé LE van Kempen, Cyra E Leurs, Anke Vennegoor [...]

Multiple Sclerosis Journal

Open access

Case report

First published 2022-2

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

Alyssa A Toorop, Theo Rispens, Eva MM Strijbis [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2024-2

Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis

Alyssa A Toorop, Samantha Noteboom, Martijn D Steenwijk [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2023-3

Fingerprick blood samples to measure serum natalizumab concentrations

Alyssa A Toorop, Maurice Steenhuis, Floris C Loeff [...]

Multiple Sclerosis Journal

Retricted access

Letter

First published 2018-5

Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Tony Sehr, Undine Proschmann, Katja Thomas [...]

Multiple Sclerosis Journal

Retricted access

Editorial

First published 2017-6

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations

Clemens Warnke, Hans-Peter Hartung

Multiple Sclerosis Journal

Open access

Letter

First published 2018-5

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Zoé LE van Kempen, Theo Rispens, Joep Killestein

Multiple Sclerosis Journal

Open access

Research article

First published 2022-2

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary

Ruth Dobson, Karen Chung

Multiple Sclerosis Journal

Search results